IMI announces a new total of 23 unique projects to boost drug innovation

The Innovative Medicines Initiative (IMI), currently the largest public-private partnership in the biopharmaceutical sector, launches its second wave of research projects which address key areas including cancer, immune-mediated diseases, infectious disorders and electronic health. With 23 projects now up and running, over €450 million is now committed by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) on a uniquely large scale. IMI is shaping the current and future research and development of innovative drugs in Europe.

Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science said: "By speeding up drug development across Europe, the investments made by the IMI will ultimately save and improve lives, as well as making a major contribution to the Innovation Union and to growth and jobs."

With a budget of €172 million, 8 new IMI projects are being launched over the coming weeks. The project consortia include 21 EFPIA members represented by 65 EFPIA teams who are working together with partners from 103 academic teams, 23 SMEs and 2 patient organisations.

Roch Doliveux, CEO of UCB and member of the Board of the European Federation of Pharmaceutical Association (EFPIA) says, "The industry has reached an inflection point where public private partnerships, based on open innovation networks, will improve the efficiency of the pharmaceutical companies in bringing safe, efficacious, cost-effective treatments to patients. EFPIA considers IMI as a key instrument to implement the new business models which will ensure the sustainability of pharmaceutical industries across Europe."

The 8 new projects deal with health concerns, identified by scientific priority and industry needs, will develop new patient treatments for cancer, rheumatoid arthritis and infectious diseases.

PREDECT, ONCOTRACK, QUIC-CONCEPT all focus on developing better tools for diagnosing and treating lung, prostate, ovarian, breast and colon cancers and are covered by IMI's 'efficacy' pillar along with RAPP-ID and BTCure which aim to facilitate the development of novel diagnostic tools related to infectious diseases and rheumatoid arthritis. DDMoRe, OPEN-PHACTS and EHR4CR fall under IMI's 'Knowledge Management' pillar in developing new methods dedicated to common standards and sharing data on common platforms for more efficient drug-development and patient treatments for the future. The projects will run for between 36 - 60 months. Detailed factsheets are available on the IMI website: www.imi.europa.eu

Ruxandra Draghia-Akli, Director Health in the Research & Innovation DG of the European Commission says, "It is encouraging that IMI is launching 8 new innovative projects in areas as different as cancer or diagnostic tools for infectious diseases. Results from IMI projects that have been selected from the first call already demonstrate how this novel public-private collaboration is delivering results that can make a difference in how drugs are developed, for the benefit of patients in Europe and worldwide."

The first-wave IMI projects, now up and running for around one year, are already providing tangible benefits, delivered through the constructive engagement of industry competitors, academia, patient groups and SMEs. These first contributions are made possible by the collaborative spirit of scientists from industry and academia along with SMEs, patient organisations and regulatory agencies who form the IMI project consortia.

Michel Goldman, Executive Director of IMI says, "The uniqueness of what IMI is doing to facilitate innovation in the biopharmaceutical sector is the scale of the collaborative research now being undertaken and it’s changing how drug development happens. It is clear that IMI is performing a vital role in working towards finding better solutions for patients across Europe."

IMI is fostering a new environment of collaboration and innovation to shape the future of the biopharmaceutical sector in Europe.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...